肝细胞癌患者外周血单个核细胞Foxp3 mRNA水平变化*

doi:10.3969/j.issn.1672-5069.2015.04.016

Abstract

Abstract: Objective To investigate Foxp3 mRNA levels in peripheral blood mononuclear cells （PBMCs） in patients with hepatocellular carcinoma（HCC） and explore its relationship with serum AFP levels. Methods 60 patients with HCC and 20 healthy persons were enrolled in this study. The Foxp3 mRNA in PBMCs was measured by RT-PCR and serum AFP was detected at the same time. Results There existed statistically significant difference in Foxp3 levels between patients with HCC and controls[（0.976±0.073） vs.（0.772±0.083），P<0.01]； Pearson correlation analysis showed positive correlation between Foxp3 levels in PBMCs and serum AFP levels in HCC patients（r＝0.226，P＝0.025）. Conclusion The Foxp3 levels in PBMCs in patients with HCC increase，which might help predict HCC development.

Key words: Hepatocellular carcinoma, Foxp3, Peripheral blood mononuclear cells, Alpha fetal protein

Yang Zhi，Chen Hongtao，Wu Shipin. Foxp3 mRNA in peripheral blood mononuclear cells in patients with hepatocellular carcinoma[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(4): 395-398.

References

[1] Llovet JM，Burroughs A，Bruix J. Hepatocellular carcinoma. Lancet，2003，362:1907-1917.
[2] Forner A，Llovet JM，Bruix J. Hepatocellular carcinoma.Lancet，2012，379:1245-1255.
[3] Jemal A，Murray T，Ward E，et al. Cancer statistics，2005. CA Cancer J Clin，2005，55:10-30.
[4] Budhu A，Forgues M，Ye QH，et al. Prediction of venous metastases，recurrence，and prognosis in hepatocellular carcinoma based on a unique immune response signature on the liver micro-environment. Cancer Cell，2006，10:99.
[5] Kaibori M，Kubo S，Nagano H，et al. Clinicopathological features of recurrence in patients after 10-year disease-free survival following curative hepatic resection of hepatocellular carcinoma. World J Surg，2013，37（4）:820.
[6] Sakaguchi S，Sakaguchi N，Asano M，et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains（CD25）. Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol，1995，155:1151-1164.
[7] Pedroza-Gonzalez A，Verhoef C，Ijzermans JN，et al. Activated tumor-infiltrating CD+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer. Hepatology，2013，57（1）:183.
[8] 李巍，叶研硕，刘宏宇，等. 调节性Ｔ细胞在肝癌发生发展中的作用及机理. 中国实验诊断学，2013，17（12）:312-314.
[9] Zhao HQ，Li WM，Lu ZQ，et al. Roles of Tregs in development of hepatocellular carcinoma:A meta-analysis. World J Gastroenterol，2014，20（24）:7971-7978.
[10] Yagi H，Nomura T，Nakamura K，et al. Crucial role of FOXP3 in the development and function of human CD+25CD+4 regulatory T cells. Int Immunol，2004，16（11）:1643-1656.
[11] Shevach EM. Certified professionals:CD4（+）CD25（+） suppressor T cells. J Exp Med，2001，193（11）:41-46.
[12] Fontenot JD，Gavin MA，Rudensky AY.Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol，2003，4:330.
[13] Sakaguchi S，Sakaguchi N，Shimizu J，et al. Immunologic tolerance maintained by CD25+CD4+ regulatory T cells:their common role in controlling autoimmunity，tumor immunity， and transplantation tolerance. Immunol Rev，2001，182:18-32.
[14] Nishikawa H，Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer，2010，127:759-767.
[15] Fu J，Xu D，Liu Z，et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology，2007，132:2328-2339.
[16] Hori S，Nomura T，Sakaguchi TJ. Control of regulatory T cell development by the transcription factor Foxp3. Science，2003，299:1057-1061.
[17] Levy MY，Sidana A，Chowdhury WH，et al. Cyclophosphamide unmasks an anti-metastatic effect of local tumor cryoablation. J Pharmacol Exp Ther，2009，330:596-601.
[18] Yamaguchi T，Sakaguchi S. Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol，2006，16:115-23.
[19] Khazaie K，von Boehmer H. The impact of CD4+CD25+ Treg on tumor specific CD8+T cell cytotoxicity and cancer. Semin Cancer Biol，2006，16:124-36.
[20] Curiel TJ，Coukos G，Zou L，et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med，2004，10:942-949.
[21] Sasada T，Kimura M，Yoshida Y，et al. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies:possible involvement of regulatory T cells in disease progression. Cancer，2003，98:1089-1099.
[22] Ormandy LA，Hillemann T，Wedemeyer H，et al. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res，2005，65:2457-2464.
[23] Stoop JN，van der Molen RG，Baan CC，et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology，2005，41:771-778.
[24] Wolf AM，Wolf D，Steurer M，et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res，2003，9:606-612.
[25] Miller AM，Lundberg K，Ozenci V，et al. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol，2006，177:7398-7405.
[26] Frey DM，Droeser RA，Viehl CT，et al. High frequency of tumor-infiltrating FOXP3（+） regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer，2010，126:2635-2643.
[27] Baecher-Allan C，Anderson DE. Regulatory cells and human cancer. Semin Cancer Biol，2006，16:98-105.
[28] Lee MK，Moore DJ，Jarrett BP，et al. Promotion of allograft survival by CD4+CD25+ regulatory T cells:Evidence for in vivo inhibition of effector cell proliferation. J Immunol，2004，172:6539.
[29] Casares N，Arribillaga L，Sarobe P，et al. CD+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+T cells with IFN-gamma-dependent anti- angiogenic activity，as well as long-lasting tumor immunity elicited by peptide vaccination.J Immunol，2003，171:5931.
[30] Unitt E，Rushbrook SM，Marshal LA，et al. Compromised lymphocytes infiltrate hepatocellular carcinoma:the role of T-regulatory cells. Hepatology，2005，41:722-730.

Foxp3 mRNA in peripheral blood mononuclear cells in patients with hepatocellular carcinoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Cao Ce, Yu Yixing, Wang Beibei, et al.. Clinical diagnostic efficacy of enhanced magnetic resonance imaging combined with serum AFP and PIVKA-Ⅱ in the diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 896-899.
[2]	Xing Hao, Han Jun, Yang Tian.. Diagnostic value of serum protein induced by vitamin K absence or antagonist II for hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 934-937.
[3]	Zhu Jun, Ding Ying, Wang Shiqing, et al. Peripheral blood Th22 cells and plasma interleukin-22 level changes in patients with hepatocellular carcinoma after hepatectomy and administration of ulinastatin [J]. Journal of Practical Hepatology, 2019, 22(5): 720-723.
[4]	Wang Gang, Zhao Hongbo, Zhu Yaling, et al. Cancerous XPO5 gene level in patients with hepatocellular carcinoma and its clinical significance [J]. Journal of Practical Hepatology, 2019, 22(5): 724-727.
[5]	Qiao Zhizhong. Value of contrast-enhanced ultrasonography in differential diagnosis of patients with focal nodular hyperplasia and hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 421-424.
[6]	Zhu Guangxi，Wen Liangzhi，Chen Dongfeng. Pathogenesis of non-alcoholic fatty liver disease-related hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 453-456.
[7]	Wang Huming, Fan Dongsheng, Xu Jie, Liu Xianfegn, Zhou Ning, Li Min, Bao Nana. Cancerous miRNA-30c levels affecting the survival of patients with hepatocellular carcinoma after hepatectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 248-251.
[8]	Xing Diankui, Cheng Jing. Clinical value of ¹⁸F-FDG PET/CT scan in patients with hepatocellular carcinoma and hepatic microvascular invasion [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 252-254.
[9]	Wang Xiuqing, Ma Yanjun, Zhan Jinli. Efficacy of transcatheter arterial chemoembolization and ultrasound-guided microwave ablation in the treatment of patients with hepatocellular carcinoma at special sites [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 260-263.
[10]	Zhang Xiaozhou, Shuai Ling, Wang Qingda, Yang Nan. Changes of serum miR-335 levels in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 268-271.
[11]	Wang Zhaoxia, Guan Ke, Fu Sanxian, Wang Huijie. Early administration of enteral nutrition in patients with hepatocellular carcinoma undergoing hepatectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 272-275.
[12]	Zhao Xitai, Nie Qinghe. Serum microRNA in diagnosis of patients with hepatocellular carcinoma and methodological progress [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 297-300.
[13]	Fan Jiangao.. Highlights of Journal of Practical Hepatology in 2018 [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 1-3.
[14]	Chen Yongqi, Chen Qian, Yuan Chunyan, et al.. Cancerous and noncancerous expression of Ep-CAM and C-Kit in patients with hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 109-112.
[15]	Ouyang Shi, Chen Xiaoping, Cheng Tao, et al.. Correlation of HLA-A,-B,-C,-DRB1,-DQB1 alleles to hepatocellular carcinoma development in patients with hepatitis B viral infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 940-946.